Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01741415
Other study ID # R01DA032582
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 13, 2013
Est. completion date September 1, 2019

Study information

Verified date May 2017
Source University of South Florida
Contact Kelly Lane, BA
Phone 813-974-9030
Email kellylane@mail.usf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite recent advances in substance abuse interventions, a large percentage of clients entering residential treatment for substance use will drop out of treatment prematurely, and of the remaining, many will relapse soon after treatment completion. Previous research indicates that an individual's ability to withstand psychological distress is a key factor necessary to maintain drug and alcohol abstinence and to remain in substance use treatment without absconding. In previous work, Dr. Bornovalova developed a specific distress tolerance treatment called Skills for Improving Distress Intolerance (SIDI). This intervention features skills training in behavioral and acceptance strategies and intentional clinical exposure to emotional distress. SIDI was developed and piloted with a sample of urban drug users seeking treatment in a residential facility. Individuals receiving SIDI exhibited greater improvement in distress tolerance than those in two comparison groups (receiving treatment-as-usual and supportive counseling).

Current study. The investigators received NIDA funding to conduct a randomized clinical trial with 325 clients entering a residential substance use treatment facility. Study participants will be randomized into two treatment groups: (1) those receiving SIDI and (2) those receiving Supportive Counseling (SC). Participants will receive 10 treatment sessions over a period of 4 months. Then, the investigators will follow clients for one year to examine treatment retention and abstinence.


Recruitment information / eligibility

Status Recruiting
Enrollment 325
Est. completion date September 1, 2019
Est. primary completion date September 12, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion criteria:

- 18-65 years of age

- Not evidencing severe cognitive deficits

- Ability to give informed consent

Exclusion criteria:

- <18 years of age or > 65 years of age

- Not evidencing severe cognitive deficits (site designation of 'not competent to stand trial')

- Unable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
SIDI

SC


Locations

Country Name City State
United States Agency for Community Treatment Services, Inc Tarpon Springs Florida

Sponsors (1)

Lead Sponsor Collaborator
University of South Florida

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other successful/unsuccessful completion of residential addictions treatment successful/unsuccessful completion of residential addictions treatment Baseline, post-treatment (at 3 month mark in residential facility), successful discharge within 6 months from residential facility
Other time in jail measured by public records (# of days in jail by each timepoint) 1, 3, 6 month follow-up in community
Other psychiatric distress psychiatric distress on brief symptom inventory post-treatment at 3 month mark in residential facility, 1, 3, 6 month follow-up in community
Other maladaptive personality change in maladaptive personality on the Personality Inventory for DSM5 post-treatment (at 3 month mark in residential facility), 1, 3, 6 month follow-up in community
Primary abstinence at 1, 3, 6 & 12 month follow-up Measured via biological verification and timeline follow-back 1, 3, 6 month follow-up post-treatment
Secondary distress tolerance ability to tolerate psychological distress 1, 3, 6 month follow-up
See also
  Status Clinical Trial Phase
Completed NCT00887367 - EtOH Interaction Study Phase 1
Completed NCT01036061 - GSK618334 Repeat Dose Study Phase 1
Completed NCT01189799 - Motivational Therapy for Substance Users With Depression N/A
Completed NCT01381133 - Adolescent Outpatient and Continuing Care Study Phase 3
Recruiting NCT04430257 - Pre-exposure Prophylaxis (PrEP) for Health N/A
Completed NCT01128140 - Efficacy Trial of Warrior Check-Up Phase 2
Completed NCT03767907 - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial N/A
Recruiting NCT05833399 - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn NCT01515917 - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI) N/A
Completed NCT00208143 - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Phase 4
Withdrawn NCT03762798 - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone N/A
Completed NCT03048552 - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 N/A
Active, not recruiting NCT04768920 - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD) N/A
Recruiting NCT05410561 - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients N/A
Recruiting NCT05679284 - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn NCT00908206 - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics Phase 1
Recruiting NCT05348317 - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders N/A
Active, not recruiting NCT01621711 - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2
Completed NCT00288886 - Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment Phase 2